過活動膀胱治療の世界市場レポート 2025年

過活動膀胱治療市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR5.2％で39億9,000万米ドルに成長します。予測期間の成長は、高齢化、先進治療、個別化医療、ヘルスケア投資、患者中心のケアに起因しています。予測期間の主な動向としては、非薬理学的介入、デジタルヘルスソリューション、代替医療の受容、性別に特化したアプローチ、ホリスティックケアなどが挙げられます。

過活動膀胱治療市場は、高齢者人口の増加に牽引され、成長を遂げようとしています。65歳以上を含む高齢者層は、尿量の減少、過活動膀胱、前立腺肥大、腎結石などの要因により尿路感染症に罹患しやすく、過活動膀胱の症状をターゲットとした治療に対する需要が高まっています。ReliefWebが2022年7月に報告したように、65歳以上の世界人口は2022年の10％から2050年には16％に増加し、2050年には総人口の23％を占める9,400万人に達すると予測されています。このように、老人人口の拡大は過活動膀胱治療市場の成長を促進する重要な要因です。

膀胱がんの流行も過活動膀胱治療市場の成長を促す重要な要因です。膀胱がんは、膀胱内の異常な細胞増殖を特徴とし、しばしば過活動膀胱の症状を示します。こうした症状を治療することは、膀胱がん患者の生活の質を向上させるために極めて重要です。米国臨床腫瘍学会の2023年3月の推計によると、米国の成人約82,290人が膀胱がんと診断され、2023年には約16,710人が死亡すると予想されています。このことは、膀胱がんと過活動膀胱の有病率の相関関係を強調し、市場の成長に寄与しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界過活動膀胱治療PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、制約）
• 最終用途産業の分析
• 世界の過活動膀胱治療市場：成長率分析
• 世界の過活動膀胱治療市場の実績：規模と成長, 2019-2024
• 世界の過活動膀胱治療市場の予測：規模と成長, 2024-2029, 2034F
• 世界過活動膀胱治療総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の過活動膀胱治療市場病気の種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 特発性膀胱過活動症
• 神経因性膀胱過活動
• 世界の過活動膀胱治療市場セラピーによって、実績と予測, 2019-2024, 2024-2029F, 2034F
• 抗コリン薬
• ミラベグロン
• 神経刺激
• 膀胱内注入
• その他の治療法
• 世界の過活動膀胱治療市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• ドラッグストアと薬局
• オンラインプロバイダー
• 世界の過活動膀胱治療市場特発性膀胱過活動症のタイプ別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 切迫性尿失禁
• 緊急頻度
• 世界の過活動膀胱治療市場神経因性膀胱過活動のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 脊髄損傷に関連する過活動
• 多発性硬化症に関連する過活動
• 脳卒中に関連する過活動

第7章 地域別・国別分析

• 世界の過活動膀胱治療市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の過活動膀胱治療市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 過活動膀胱治療市場：競合情勢
• 過活動膀胱治療市場：企業プロファイル
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Astellas Pharma Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Laborie Medical Technologies Corporation Overview, Products and Services, Strategy and Financial Analysis
  • Endo International plc Overview, Products and Services, Strategy and Financial Analysis
  • Hisamitsu Pharmaceutical Co. Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Johnson & Johnson Services Inc.
• Medtronic plc
• Pfizer Inc.
• Sanofi SA
• Teva Pharmaceutical Industries Limited
• Cogentix Medical Inc.
• Dr. Reddy's Laboratories Ltd.
• Sumitomo Pharma Co. Ltd.
• Sun Pharmaceutical Industries Ltd.
• Intas Pharmaceuticals Limited
• Merck & Co. Inc.
• Macleods Pharmaceuticals Ltd.
• Bayer AG
• Boehringer Ingelheim International GmbH
• Eli Lilly and Company

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 過活動膀胱治療市場2029：新たな機会を提供する国
• 過活動膀胱治療市場2029：新たな機会を提供するセグメント
• 過活動膀胱治療市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Overactive bladder encompasses a range of symptoms that can impact a person's frequency of urination and the sense of urgency. Treatment involves modifying specific behaviors, incorporating pelvic floor muscle exercises, and other measures aimed at alleviating symptoms. The objective of treatment is to effectively address the symptoms of an overactive bladder and decrease instances of urgent incontinence.

The primary categories of diseases in the treatment of overactive bladder are idiopathic bladder overactivity and neurogenic bladder overactivity. Idiopathic bladder overactivity involves an involuntary contraction of the bladder muscle, leading to a sudden and urgent urge to urinate. This condition is managed through overactive bladder (OAB) treatment methods, including anticholinergics and beta-3 agonists. Various therapies such as anticholinergics, mirabegron, neurostimulation, intravesical instillation, and other approaches are employed to treat these diseases. These therapies are available through channels such as hospital pharmacies, drug stores, retail pharmacies, and online providers.

The overactive bladder treatment market research report is one of a series of new reports from The Business Research Company that provides overactive bladder treatment market statistics, including overactive bladder treatment industry global market size, regional shares, competitors with an overactive bladder treatment market share, detailed overactive bladder treatment market segments, market trends and opportunities, and any further data you may need to thrive in the overactive bladder treatment industry. This overactive bladder treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The overactive bladder treatment market size has grown steadily in recent years. It will grow from $3.15 billion in 2024 to $3.25 billion in 2025 at a compound annual growth rate (CAGR) of 3.3%. The growth in the historic period can be attributed to medication development, patient awareness, demographic shifts, clinical guidelines, investment in research.

The overactive bladder treatment market size is expected to see strong growth in the next few years. It will grow to $3.99 billion in 2029 at a compound annual growth rate (CAGR) of 5.2%. The growth in the forecast period can be attributed to aging population, advanced therapies, personalized medicine, healthcare investments, patient-centric care. Major trends in the forecast period include non-pharmacological interventions, digital health solutions, alternative medicine acceptance, gender-specific approaches, and holistic care.

The overactive bladder treatment market is poised for growth, driven by the increasing elderly population. With the geriatric demographic, encompassing individuals aged 65 and older, being more susceptible to urinary tract infections due to factors such as diminished urine flow, overactive bladder, enlarged prostate, or kidney stones, there is a heightened demand for treatments targeting overactive bladder symptoms. As reported in July 2022 by ReliefWeb, the global population aged 65 and older is projected to rise from 10% in 2022 to 16% in 2050, reaching 94 million individuals, constituting 23% of the total population by 2050. Thus, the expanding geriatric population is a key factor propelling the overactive bladder treatment market's growth.

The prevalence of bladder cancer is another significant driver for the growth of the overactive bladder treatment market. Bladder cancer, characterized by abnormal cell growth in the bladder, often manifests with symptoms of overactive bladder. Treating these symptoms is crucial for improving the quality of life for individuals with bladder cancer. According to the American Society of Clinical Oncology's estimation in March 2023, around 82,290 adults in the United States are anticipated to be diagnosed with bladder cancer, with approximately 16,710 deaths expected in 2023. This underscores the correlation between bladder cancer and the prevalence of overactive bladder, contributing to the market's growth.

A notable trend in the overactive bladder treatment market is the approval of new products. Leading companies in the market are investing in the development of advanced products that incorporate the latest technologies to maintain their market positions. For example, in April 2023, Avation Medical Inc., a US-based company specializing in advanced neuromodulation and digital health, received FDA clearance for The Vivally System. This non-invasive bladder control therapy device, along with its accompanying mobile application, is designed to treat individuals suffering from urge urinary incontinence and urine urgency linked to overactive bladder syndrome. The system combines an ankle-worn garment with an intelligent controller, delivering personalized neuromodulation energy to the tibial nerve.

Major companies in the overactive bladder (OAB) treatment market are concentrating on developing innovative, cost-effective solutions to lower healthcare expenses and enhance patient adherence. Cost-effective solutions deliver favorable results or achieve their intended objectives at a lower cost than alternatives. For example, in April 2024, Zydus Lifesciences Ltd., an India-based pharmaceutical firm, launched a generic drug for managing OAB, which is characterized by urinary urgency, frequency, and incontinence. This new generic medication, now available in the US market, offers a cost-effective extended-release option. While anticholinergic drugs have traditionally been used to treat OAB, newer therapies are emerging, and the introduction of generics helps reduce healthcare costs and promotes better patient adherence to treatment.

In January 2024, Boston Scientific, a US-based medical technology company, announced its agreement to acquire Axonics Inc. for $3.7 billion. This acquisition enhances Boston Scientific's portfolio in the neuromodulation market, allowing the company to broaden its offerings and improve patient outcomes. By integrating Axonics' advanced technologies, Boston Scientific intends to strengthen its capabilities in delivering comprehensive solutions for patients with urological and gastrointestinal conditions. Axonics Inc., also based in the US, specializes in developing innovative sacral neuromodulation solutions for treating bladder and bowel dysfunction.

Major companies operating in the overactive bladder treatment market include AbbVie Inc., Astellas Pharma Inc., Laborie Medical Technologies Corporation, Endo International plc, Hisamitsu Pharmaceutical Co. Inc., Johnson & Johnson Services Inc., Medtronic plc, Pfizer Inc., Sanofi SA, Teva Pharmaceutical Industries Limited, Cogentix Medical Inc., Dr. Reddy's Laboratories Ltd., Sumitomo Pharma Co. Ltd., Sun Pharmaceutical Industries Ltd., Intas Pharmaceuticals Limited, Merck & Co. Inc., Macleods Pharmaceuticals Ltd., Bayer AG, Boehringer Ingelheim International GmbH, Eli Lilly and Company, GlaxoSmithKline plc, Janssen Pharmaceuticals Inc., Novartis International AG, Daiichi Sankyo Company ltd., Boston Scientific Corporation, Grunenthal GmbH, Collegium Pharmaceutical Inc.

North America was the largest region in the overactive bladder treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the overactive bladder treatment market report during the forecast period. The regions covered in the overactive bladder treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the overactive bladder treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The overactive bladder treatment market consists of revenues earned by entities by providing treatments such as behavioral therapies, nerve stimulation, and percutaneous tibial nerve stimulation (PTNS). The market value includes the value of related goods sold by the service provider or included within the service offering. The overactive bladder treatment market also includes sales of medications used in providing overactive bladder treatment. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Overactive Bladder Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on overactive bladder treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for overactive bladder treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The overactive bladder treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Diseases Type: Idiopathic Bladder Overactivity; Neurogenic Bladder Overactivity
• 2) By Therapy: Anticholinergics; Mirabegron; Neurostimulation; Intravesical Instillation; Other Therapies
• 3) By Distribution Channel: Hospital Pharmacies; Drug Stores And Retail Pharmacies; Online Providers
• Subsegments:
• 1) By Idiopathic Bladder Overactivity: Urge Incontinence; Urgency Frequency
• 2) By Neurogenic Bladder Overactivity: Spinal Cord Injury-Related Overactivity; Multiple Sclerosis-Related Overactivity; Stroke-Related Overactivity
• Companies Mentioned: AbbVie Inc.; Astellas Pharma Inc.; Laborie Medical Technologies Corporation; Endo International plc; Hisamitsu Pharmaceutical Co. Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Overactive Bladder Treatment Market Characteristics

3. Overactive Bladder Treatment Market Trends And Strategies

4. Overactive Bladder Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Overactive Bladder Treatment Growth Analysis And Strategic Analysis Framework

• 5.1. Global Overactive Bladder Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Overactive Bladder Treatment Market Growth Rate Analysis
• 5.4. Global Overactive Bladder Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Overactive Bladder Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Overactive Bladder Treatment Total Addressable Market (TAM)

6. Overactive Bladder Treatment Market Segmentation

• 6.1. Global Overactive Bladder Treatment Market, Segmentation By Diseases Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Idiopathic Bladder Overactivity
• Neurogenic Bladder Overactivity
• 6.2. Global Overactive Bladder Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Anticholinergics
• Mirabegron
• Neurostimulation
• Intravesical Instillation
• Other Therapies
• 6.3. Global Overactive Bladder Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Drug Stores And Retail Pharmacies
• Online Providers
• 6.4. Global Overactive Bladder Treatment Market, Sub-Segmentation Of Idiopathic Bladder Overactivity, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Urge Incontinence
• Urgency Frequency
• 6.5. Global Overactive Bladder Treatment Market, Sub-Segmentation Of Neurogenic Bladder Overactivity, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Spinal Cord Injury-Related Overactivity
• Multiple Sclerosis-Related Overactivity
• Stroke-Related Overactivity

7. Overactive Bladder Treatment Market Regional And Country Analysis

• 7.1. Global Overactive Bladder Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Overactive Bladder Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Overactive Bladder Treatment Market

• 8.1. Asia-Pacific Overactive Bladder Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Overactive Bladder Treatment Market, Segmentation By Diseases Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Overactive Bladder Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Overactive Bladder Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Overactive Bladder Treatment Market

• 9.1. China Overactive Bladder Treatment Market Overview
• 9.2. China Overactive Bladder Treatment Market, Segmentation By Diseases Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Overactive Bladder Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Overactive Bladder Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Overactive Bladder Treatment Market

• 10.1. India Overactive Bladder Treatment Market, Segmentation By Diseases Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Overactive Bladder Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Overactive Bladder Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Overactive Bladder Treatment Market

• 11.1. Japan Overactive Bladder Treatment Market Overview
• 11.2. Japan Overactive Bladder Treatment Market, Segmentation By Diseases Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Overactive Bladder Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Overactive Bladder Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Overactive Bladder Treatment Market

• 12.1. Australia Overactive Bladder Treatment Market, Segmentation By Diseases Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Overactive Bladder Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Overactive Bladder Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Overactive Bladder Treatment Market

• 13.1. Indonesia Overactive Bladder Treatment Market, Segmentation By Diseases Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Overactive Bladder Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Overactive Bladder Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Overactive Bladder Treatment Market

• 14.1. South Korea Overactive Bladder Treatment Market Overview
• 14.2. South Korea Overactive Bladder Treatment Market, Segmentation By Diseases Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Overactive Bladder Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Overactive Bladder Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Overactive Bladder Treatment Market

• 15.1. Western Europe Overactive Bladder Treatment Market Overview
• 15.2. Western Europe Overactive Bladder Treatment Market, Segmentation By Diseases Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Overactive Bladder Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Overactive Bladder Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Overactive Bladder Treatment Market

• 16.1. UK Overactive Bladder Treatment Market, Segmentation By Diseases Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Overactive Bladder Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Overactive Bladder Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Overactive Bladder Treatment Market

• 17.1. Germany Overactive Bladder Treatment Market, Segmentation By Diseases Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Overactive Bladder Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Overactive Bladder Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Overactive Bladder Treatment Market

• 18.1. France Overactive Bladder Treatment Market, Segmentation By Diseases Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Overactive Bladder Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Overactive Bladder Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Overactive Bladder Treatment Market

• 19.1. Italy Overactive Bladder Treatment Market, Segmentation By Diseases Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Overactive Bladder Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Overactive Bladder Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Overactive Bladder Treatment Market

• 20.1. Spain Overactive Bladder Treatment Market, Segmentation By Diseases Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Overactive Bladder Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Overactive Bladder Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Overactive Bladder Treatment Market

• 21.1. Eastern Europe Overactive Bladder Treatment Market Overview
• 21.2. Eastern Europe Overactive Bladder Treatment Market, Segmentation By Diseases Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Overactive Bladder Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Overactive Bladder Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Overactive Bladder Treatment Market

• 22.1. Russia Overactive Bladder Treatment Market, Segmentation By Diseases Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Overactive Bladder Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Overactive Bladder Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Overactive Bladder Treatment Market

• 23.1. North America Overactive Bladder Treatment Market Overview
• 23.2. North America Overactive Bladder Treatment Market, Segmentation By Diseases Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Overactive Bladder Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Overactive Bladder Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Overactive Bladder Treatment Market

• 24.1. USA Overactive Bladder Treatment Market Overview
• 24.2. USA Overactive Bladder Treatment Market, Segmentation By Diseases Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Overactive Bladder Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Overactive Bladder Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Overactive Bladder Treatment Market

• 25.1. Canada Overactive Bladder Treatment Market Overview
• 25.2. Canada Overactive Bladder Treatment Market, Segmentation By Diseases Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Overactive Bladder Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Overactive Bladder Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Overactive Bladder Treatment Market

• 26.1. South America Overactive Bladder Treatment Market Overview
• 26.2. South America Overactive Bladder Treatment Market, Segmentation By Diseases Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Overactive Bladder Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Overactive Bladder Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Overactive Bladder Treatment Market

• 27.1. Brazil Overactive Bladder Treatment Market, Segmentation By Diseases Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Overactive Bladder Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Overactive Bladder Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Overactive Bladder Treatment Market

• 28.1. Middle East Overactive Bladder Treatment Market Overview
• 28.2. Middle East Overactive Bladder Treatment Market, Segmentation By Diseases Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Overactive Bladder Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Overactive Bladder Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Overactive Bladder Treatment Market

• 29.1. Africa Overactive Bladder Treatment Market Overview
• 29.2. Africa Overactive Bladder Treatment Market, Segmentation By Diseases Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Overactive Bladder Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Overactive Bladder Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Overactive Bladder Treatment Market Competitive Landscape And Company Profiles

• 30.1. Overactive Bladder Treatment Market Competitive Landscape
• 30.2. Overactive Bladder Treatment Market Company Profiles
  • 30.2.1. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Astellas Pharma Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Laborie Medical Technologies Corporation Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Endo International plc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Hisamitsu Pharmaceutical Co. Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Overactive Bladder Treatment Market Other Major And Innovative Companies

• 31.1. Johnson & Johnson Services Inc.
• 31.2. Medtronic plc
• 31.3. Pfizer Inc.
• 31.4. Sanofi SA
• 31.5. Teva Pharmaceutical Industries Limited
• 31.6. Cogentix Medical Inc.
• 31.7. Dr. Reddy's Laboratories Ltd.
• 31.8. Sumitomo Pharma Co. Ltd.
• 31.9. Sun Pharmaceutical Industries Ltd.
• 31.10. Intas Pharmaceuticals Limited
• 31.11. Merck & Co. Inc.
• 31.12. Macleods Pharmaceuticals Ltd.
• 31.13. Bayer AG
• 31.14. Boehringer Ingelheim International GmbH
• 31.15. Eli Lilly and Company

32. Global Overactive Bladder Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Overactive Bladder Treatment Market

34. Recent Developments In The Overactive Bladder Treatment Market

35. Overactive Bladder Treatment Market High Potential Countries, Segments and Strategies

• 35.1 Overactive Bladder Treatment Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Overactive Bladder Treatment Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Overactive Bladder Treatment Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer